by deyuz | Sep 29, 2025 | White Papers
Prescription drugs have drawn significant policy and public attention in discussions of rising health care costs in the United States. However, their actual contribution to the growth of total health care spending remains uncertain. Drawing on data from the National...
by deyuz | Sep 29, 2025 | White Papers
This policy brief evaluates the potential impact of Most Favored Nation (MFN) pricing on pharmaceutical innovation and patient health. We analyze MFN pricing being imposed in Medicare and Medicaid, requiring U.S. prices for already launched drugs to match the lowest...
by maica | Jul 21, 2025 | White Papers
This white paper is based on the Policy Brief: International Price Differences for Drug Prescriptions. The National Review also featured Professor Philipson’s oped on the same topic. Many international drug price comparisons conclude that the U.S. has the...
by sfrazee | Apr 25, 2024 | White Papers
The rapid emergence of vaccines and therapeutics in response to the onset of the coronavirus (COVID-19) pandemic demonstrated the value of medical innovation. These advances not only led to enhanced patient welfare by reducing the disease’s mortality and morbidity but...
by cmicklin | Feb 15, 2024 | White Papers
This policy brief provides a quantitative analysis of how the Inflation Reduction Act’s (IRA) policy to set prices for select small molecule drugs 9 years after FDA approval impacts innovation and patient health. Price setting under the IRA undermines existing...
by susuguo | Feb 1, 2024 | White Papers
Price theory says that the most important effects of policy and technological change are often found beyond their first point of contact. This appears opposed to econometric methods that rule out spillovers of one person’s treatment on another’s outcomes. This paper...
